Crystal form of triazolopyridine-substituted indazole compound and preparation method therefor
View Patent ↗Provided are a crystal form of a triazolopyridine-substituted indazole compound and a preparation method therefor; and specifically disclosed are a crystal form of a compound as represented by formula (I) and a preparation method therefor.
1 . A crystal form Q of a compound of formula (I), wherein the crystal form Q has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 10.301±0.200°, 17.459±0.200°, and 19.141±0.200°,
2 . The crystal form Q according to claim 1 , wherein the X-ray powder diffraction pattern of the crystal form Q comprises characteristic diffraction peaks at the following 2θ angles: 10.301±0.200°, 12.779±0.200°, 16.860±0.200°, 17.459±0.200°, 19.141±0.200°, 20.701±0.200°, 21.701±0.200°, and 24.400±0.200°.
3 . The crystal form Q according to claim 2 , wherein the X-ray powder diffraction pattern of the crystal form Q comprises characteristic diffraction peaks at the following 2θ angles: 8.060±0.200°, 10.301±0.200°, 12.779±0.200°, 16.860±0.200°, 17.459±0.200°, 17.870±0.200°, 18.639±0.200°, 19.141±0.200°, 20.701±0.200°, 21.701±0.200°, 22.579±0.200°, and 24.400±0.200°.
4 . The crystal form Q according to claim 3 , wherein the X-ray powder diffraction pattern of the crystal form Q comprises characteristic diffraction peaks at the following 2θ angles: 3.861±0.200°, 8.060±0.200°, 9.6210.200°, 10.301±0.200°, 11.500±0.200°, 12.779±0.200°, 16.860±0.200°, 17.459±0.200°, 17.870±0.200°, 18.639±0.200°, 19.141±0.200°, 20.701±0.200°, 21.701±0.200°, 22.579±0.200°, 24.400±0.200°, and 24.939±0.200°.
5 . The crystal form Q according to claim 4 , wherein the crystal form Q has an XRPD pattern as shown in FIG. 1.
6 . The crystal form Q according to claim 2 , wherein the crystal form Q has a differential scanning calorimetry curve comprising endothermic peaks with an onset at 181.4° C.±5° C.
7 . The crystal form Q according to claim 6 , wherein the crystal form Q has a DSC pattern as shown in FIG. 2 .
8 . The crystal form Q according to claim 2 , wherein the crystal form Q has a thermogravimetric analysis curve with a weight loss of 1.47% at 150° C.±3° C.
9 . The crystal form Q according to claim 8 , wherein the crystal form Q has a TGA pattern as shown in FIG. 3 .
10 . A crystal form S of a compound of formula (I), wherein the crystal form S has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 13.019±0.200°, 19.579±0.200°, and 20.262±0.200°,
11 . The crystal form S according to claim 10 , wherein the X-ray powder diffraction pattern of the crystal form S comprises characteristic diffraction peaks at the following 2θ angles: 11.999±0.200°, 13.019±0.200°, 14.961±0.200°, 18.182±0.200°, 19.579-0.200°, 20.262±0.200°, 22.939±0.200°, and 24.021±0.200°.
12 . The crystal form S according to claim 11 , wherein the X-ray powder diffraction pattern of the crystal form S comprises characteristic diffraction peaks at the following 2θ angles: 3.201±0.200°, 11.463±0.200°, 11.999±0.200°, 13.019±0.200°, 14.523±0.200°, 14.961±0.200°, 18.182±0.200°, 19.579±0.200°, 20.262±0.200°, 22.939±0.200°, 24.021±0.200°, and 25.738±0.200°.
13 . The crystal form S according to claim 12 , wherein the crystal form S has an XRPD pattern as shown in FIG. 5 .
14 . The crystal form S according to claim 10 , wherein the crystal form S has a differential scanning calorimetry curve comprising an endothermic peak at 114.9° C.±3° C.
15 . The crystal form S according to claim 14 , wherein the crystal form S has a DSC pattern as shown in FIG. 6 .
16 . The crystal form S according to claim 10 , wherein the crystal form S has a thermogravimetric analysis curve with a weight loss of 0.99% at 90.0° C.±3° C. and a weight loss of 2.54% at 120.0° C.±3° C.
17 . The crystal form S according to claim 16 , wherein the crystal form S has a TGA pattern as shown in FIG. 7 .
18 . A method for treating rheumatoid arthritis in a subject in need thereof, comprising: administering the crystal form Q according to claim 1 to the subject.
19 . A method for treating rheumatoid arthritis in a subject in need thereof, comprising: administering the crystal form S according to claim 10 to the subject.